COLL Sep 2024 35.000 put
- GlobeNewswire
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
STOUGHTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of
- Insider Monkey
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Upgraded by Jefferies
We recently compiled the list of the 10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts. In this article, we are going to take a look at where Collegium Pharmaceutical, Inc. (NASDAQ:COLL) stands against the other stocks that received an upgrade from Wall Street analysts. But first, we are going to take a […]
- Investing.com
Street calls of the week: Upgrades for Best Buy and Lululemon
Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week: upgrades for Best Buy , Lululemon and Collegium Pharma; downgrade for Maxeon Solar and Medifast.
